The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?

OBJECTIVE: To investigate the effect of pharmacological treatment of SpA on depressive symptoms and explore whether this effect differs between drug classes. METHODS: Data from the observational Assessment of SpondyloArthritis international Society Health Index Validation Study were used. Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Webers, Casper, Kiltz, Uta, Braun, Jürgen, van der Heijde, Désirée, Boonen, Annelies
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234195/
https://www.ncbi.nlm.nih.gov/pubmed/36205588
http://dx.doi.org/10.1093/rheumatology/keac580
_version_ 1785052432842096640
author Webers, Casper
Kiltz, Uta
Braun, Jürgen
van der Heijde, Désirée
Boonen, Annelies
author_facet Webers, Casper
Kiltz, Uta
Braun, Jürgen
van der Heijde, Désirée
Boonen, Annelies
author_sort Webers, Casper
collection PubMed
description OBJECTIVE: To investigate the effect of pharmacological treatment of SpA on depressive symptoms and explore whether this effect differs between drug classes. METHODS: Data from the observational Assessment of SpondyloArthritis international Society Health Index Validation Study were used. Patients were assessed at baseline and after initiation of NSAIDs/conventional synthetic DMARDs (csDMARDs)/TNF inhibitors (TNFis). Depressive symptoms were assessed with the Hospital Anxiety and Depression Scale depression subscale [HADS-D; 0–21 (best–worst)]. Covariables included demographics and disease characteristics, including disease activity [Ankylosing Spondylitis Disease Activity Score (ASDAS)/BASDAI]. The change in HADS-D from baseline was compared between treatments (NSAIDs/csDMARDs/TNFis) with analysis of variance and multivariable regression analysis. RESULTS: A total of 304 patients were included; 102/45/157 initiated NSAIDs/csDMARDs/TNFis and 260 (85%) / 44 (15%) had axial/peripheral SpA. At baseline, the mean HADS-D was 6.9 (s.d. 4.2); 126 (42%) were possibly depressed (HADS-D ≥8) and 66 (22%) were probably depressed (HADS-D ≥11). At follow-up, depressive symptoms significantly improved in all treatment groups. In multivariable regression without disease activity measures, initiating TNFis compared with NSAIDs was associated with greater improvement in depressive symptoms [β = −1.27 (95% CI −2.23, −0.32)] and lower odds of possible depression at follow-up [odds ratio 0.47 (95% CI 0.23, 0.94)]. This association was attenuated after additional adjustment for disease activity (ASDAS/BASDAI) but not CRP. csDMARDs did not differ from NSAIDs regarding their effect on HADS-D. Between-drug class results were confirmed in axial SpA (axSpA), although less clear in peripheral SpA. CONCLUSION: Treatment of active SpA also improves depressive symptoms. Especially in axSpA, TNFis have a greater effect than NSAIDs, which is mainly explained by a stronger effect on disease activity. We found no evidence for a direct link between CRP-mediated inflammation and depressive symptoms in SpA.
format Online
Article
Text
id pubmed-10234195
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102341952023-06-02 The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter? Webers, Casper Kiltz, Uta Braun, Jürgen van der Heijde, Désirée Boonen, Annelies Rheumatology (Oxford) Clinical Science OBJECTIVE: To investigate the effect of pharmacological treatment of SpA on depressive symptoms and explore whether this effect differs between drug classes. METHODS: Data from the observational Assessment of SpondyloArthritis international Society Health Index Validation Study were used. Patients were assessed at baseline and after initiation of NSAIDs/conventional synthetic DMARDs (csDMARDs)/TNF inhibitors (TNFis). Depressive symptoms were assessed with the Hospital Anxiety and Depression Scale depression subscale [HADS-D; 0–21 (best–worst)]. Covariables included demographics and disease characteristics, including disease activity [Ankylosing Spondylitis Disease Activity Score (ASDAS)/BASDAI]. The change in HADS-D from baseline was compared between treatments (NSAIDs/csDMARDs/TNFis) with analysis of variance and multivariable regression analysis. RESULTS: A total of 304 patients were included; 102/45/157 initiated NSAIDs/csDMARDs/TNFis and 260 (85%) / 44 (15%) had axial/peripheral SpA. At baseline, the mean HADS-D was 6.9 (s.d. 4.2); 126 (42%) were possibly depressed (HADS-D ≥8) and 66 (22%) were probably depressed (HADS-D ≥11). At follow-up, depressive symptoms significantly improved in all treatment groups. In multivariable regression without disease activity measures, initiating TNFis compared with NSAIDs was associated with greater improvement in depressive symptoms [β = −1.27 (95% CI −2.23, −0.32)] and lower odds of possible depression at follow-up [odds ratio 0.47 (95% CI 0.23, 0.94)]. This association was attenuated after additional adjustment for disease activity (ASDAS/BASDAI) but not CRP. csDMARDs did not differ from NSAIDs regarding their effect on HADS-D. Between-drug class results were confirmed in axial SpA (axSpA), although less clear in peripheral SpA. CONCLUSION: Treatment of active SpA also improves depressive symptoms. Especially in axSpA, TNFis have a greater effect than NSAIDs, which is mainly explained by a stronger effect on disease activity. We found no evidence for a direct link between CRP-mediated inflammation and depressive symptoms in SpA. Oxford University Press 2022-10-07 /pmc/articles/PMC10234195/ /pubmed/36205588 http://dx.doi.org/10.1093/rheumatology/keac580 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Webers, Casper
Kiltz, Uta
Braun, Jürgen
van der Heijde, Désirée
Boonen, Annelies
The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
title The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
title_full The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
title_fullStr The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
title_full_unstemmed The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
title_short The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
title_sort effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234195/
https://www.ncbi.nlm.nih.gov/pubmed/36205588
http://dx.doi.org/10.1093/rheumatology/keac580
work_keys_str_mv AT weberscasper theeffectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter
AT kiltzuta theeffectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter
AT braunjurgen theeffectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter
AT vanderheijdedesiree theeffectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter
AT boonenannelies theeffectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter
AT weberscasper effectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter
AT kiltzuta effectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter
AT braunjurgen effectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter
AT vanderheijdedesiree effectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter
AT boonenannelies effectofantiinflammatorytreatmentondepressivesymptomsinspondyloarthritisdoesthetypeofdrugmatter